At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 388 enrolled
Drug / intervention
AR101biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE) Follow-on Study
In Brief
A Phase 3 clinical trial evaluating AR101 for Peanut Allergy. Completed, enrolled 388 participants across 65 sites in 9 countries.
Detailed Summary
The purpose of this study is to demonstrate the safety, tolerability, and efficacy of AR101 through oral immunotherapy (OIT) in peanut-allergic children and adults who have completed the ARC003 study.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPeanut Allergy
CountriesCanada, Germany, Ireland, Italy, Netherlands, Spain, Sweden, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2017201820192020202120222023202420252026
First PostedDec 2016
Enrollment StartDec 2016
Primary CompletionMay 2019
TodayJul 2026
First PostedDec 15, 2016
Enrollment StartDec 29, 2016
Primary CompletionMay 31, 2019
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 9.5 years ago
Interventions
AR101biological
AR101 powder provided in capsules \& sachets